Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula
Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula: A Novel Strategy for Managing Anal Fistula
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34893
- Recruiting
- MarmaraUSM
-
Contact:
- M.Unit Ugurlu, MD
- Phone Number: +905324108010
- Email: umitugurlu@gmail.com
-
Sub-Investigator:
- M.Umit Ugurlu, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
All patients with the diagnosis of anal fistula Patients with recurrence
Exclusion Criteria:
Patients who do not sign the informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Silver Nitrate
Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of anal fistula patients treated with silver nitrate solution.
Time Frame: 1 year
|
The primary end point in the study was to assess the efficacy of the silver nitrate in the treatment of anal fistula.
The number of anal fistula patients who are treated with silver nitrate solution will be calculated.
The role of silver nitrate solution in anal fistula treatment will be investigated
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapeutic factors
Time Frame: 1 year
|
The secondary end point was to identify the clinical and therapeutic factors that significantly affect the primary endpoint.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: S.CUMHUR YEGEN, MD, Marmara University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MarmaraUSM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.